DDInter1665 DDInter1658
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Sibutramine {u} (Compound) treats {v} (Disease) obesity
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
Sibutramine {u} (Compound) upregulates {v} (Gene) CDK6
Sibutramine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Sibutramine {u} (Compound) downregulates {v} (Gene) MRPL19
Sibutramine {u} (Compound) causes {v} (Side Effect) Bursitis
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinzaparin
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Sibutramine (Compound) treats obesity (Disease)
Sibutramine (Compound) binds CYP3A4 (Gene)
Sibutramine (Compound) upregulates CDK6 (Gene)
Sibutramine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Sibutramine (Compound) downregulates MRPL19 (Gene)
Sibutramine (Compound) causes Bursitis (Side Effect)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam